| ■ 영문 제목 : Global HIV Drugs Market | |
![]() | ■ 상품코드 : IRTNTR75747-23 ■ 조사/발행회사 : Technavio ■ 발행일 : 2023년 6월 최신판(2025년 또는 2026년)은 문의주세요. ■ 페이지수 : 약120 ■ 작성언어 : 영문 ■ 보고서 형태 : PDF ■ 납품 방식 : E메일 (주문후 24시간내) ■ 조사대상 지역 : 글로벌 ■ 산업 분야 : 의약품 |
| Single User (1인 열람용) | USD2,500 ⇒환산₩3,500,000 | 견적의뢰/주문/질문 |
| Enterprise License (기업 열람용) | USD4,000 ⇒환산₩5,600,000 | 견적의뢰/주문/질문 |
|
※가격옵션 설명 - 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다. - 지불방법은 계좌이체/무통장입금 또는 카드결제입니다. |
| 세계의 HIV 치료제 시장 2023-2027 HIV 치료제 시장은 2022~2027년 14억 4,771만 1,000만 달러로 성장하며, 예측 기간 동안 5.46%의 CAGR을 기록할 것으로 예상됩니다. 이 보고서는 HIV 치료제 시장에 대한 전반적인 분석, 시장 규모와 예측, 동향, 성장 촉진 요인, 과제, 그리고 약 25개 벤더에 대한 벤더 분석을 담고 있습니다. 현재 시장 시나리오, 최신 동향 및 촉진 요인, 전체 시장 환경에 대한 최신 분석을 제공합니다. 이 시장은 전 세계 HIV 에이즈 유병률의 증가, 관련 위험 요소의 사례 증가, 노인 인구의 급격한 증가에 의해 주도되고 있습니다. Technavio사의 HIV 치료제 시장은 다음과 같이 구분됩니다. 유통 채널별 - 오프라인 - 온라인 치료법별 - 병용 HIV 치료제 - 인테그라제 억제제 - 비뉴클레오시드계 역전사효소 억제제 - 기타 지역별 - 북미 - 아시아 - 아시아 - 기타 지역(ROW) 이 보고서는 HIV 치료 접근성 확대가 향후 몇 년 동안 HIV 치료제 시장의 성장을 촉진하는 주요 요인 중 하나라고 분석하고 있습니다. 또한, 표적 치료제에 대한 수요 증가와 HIV 바이러스 진단 방법의 발전은 시장의 큰 수요로 이어질 것으로 예상되고 있습니다. HIV 치료제 시장에 대한 보고서는 다음과 같은 분야를 다루고 있습니다. - HIV 치료제 시장 규모 - HIV 치료제 시장 예측 - HIV 치료제 시장 산업 분석 강력한 벤더 분석은 고객이 시장에서의 입지를 향상시킬 수 있도록 설계되었으며, 이에 따라 이 보고서는AbbVie Inc., Aspen Pharmacare Holdings Ltd, Aurobindo Pharma Ltd., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Cipla Ltd., Emcure Pharmaceuticals Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Hetero Labs Ltd., Johnson and Johnson Services Inc., Lupin Ltd., Macleods Pharmaceuticals Ltd., Merck and Co. Inc., Strides Pharma Science Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Viatris Inc., 및 Cadila Pharmaceuticals Ltd. 등의 기업을 분석하고 있습니다. 또한, HIV 치료제 시장 분석 보고서에는 시장 성장에 영향을 미치는 향후 동향과 과제에 대한 정보도 포함되어 있습니다. 이는 기업이 전략을 수립하고 다가오는 모든 성장 기회를 활용하는 데 도움이 될 수 있습니다. 이 연구는 업계 주요 참여자들의 의견을 포함하여 1차 및 2차 정보를 객관적으로 결합하여 수행되었습니다. 이 보고서는 주요 벤더에 대한 분석과 함께 포괄적인 시장 및 벤더 현황을 제공합니다. 이 보고서는 이익, 가격, 경쟁, 프로모션 등 주요 매개변수를 분석하여 여러 출처의 데이터를 조사, 통합, 요약하는 방식으로 시장의 상세한 모습을 제시합니다. 또한, 주요 산업 영향력자를 식별하여 시장의 다양한 측면을 제시합니다. 제시된 데이터는 포괄적이고 신뢰할 수 있는 1차 및 2차에 걸친 광범위한 조사 결과입니다. 시장 조사 보고서는 정확한 시장 성장을 예측하기 위해 완전한 경쟁 환경과 정성적 및 정량적 조사를 통한 면밀한 벤더 선정 방법 및 분석을 제공합니다. |
1. 개요
2. 세계의 HIV 치료 시장 현황
3. 세계의 HIV 치료 시장 규모
4. 과거 시장 규모
5. 파이브 포스 분석
6. 유통 채널별 시장 분석
7. 치료법별 시장 분석
8. 고객 현황
9. 지역별 분석
10. 추진 요인/과제/동향
11. 기업 현황
12. 기업 분석
13. 부록
1 요약 3 시장 규모 표 19: 유통 채널 부문 시장 규모 추이 2017-2021 (백만 달러) 표 20: 치료 부문 시장 규모 추이 2017-2021 (백만 달러) 표 21: 지역 부문 시장 규모 추이 2017-2021 (백만 달러) 표 22: 국가 부문 시장 규모 추이 2017-2021 (백만 달러) o 5.1 5가지 경쟁요인 요약 o 표 52: 인테그라제 억제제 차트 – 2022-2027년 시장 규모 및 전망(백만 달러) 9 지역별 현황 o 표 71: 북미 – 시장 규모 및 전망 2022-2027 차트 (백만 달러) o 표 75: 유럽 – 시장 규모 및 전망 2022-2027 차트 (백만 달러) o 표 103: 캐나다 시장 규모 및 전망 차트 2022-2027 (백만 달러) 첨부 자료: 표 1: 요약 – 시장 개요 차트 표 31: 유통 채널별 시장 점유율 데이터 표 (2022-2027년, %) 표 32: 유통 채널별 비교 차트 표 33: 유통 채널별 비교 데이터 표 표 34: 오프라인 시장 규모 및 전망 차트 (2022-2027년, 백만 달러) 표 35: 오프라인 시장 규모 및 전망 데이터 표 (2022-2027년, 백만 달러) 표 36: 오프라인 시장 – 2022-2027년 전년 대비 성장률(%) 차트 첨부자료 60: 기타 부문 시장 규모 및 전망 차트 2022-2027 (백만 달러) 첨부자료 62: 기타 부문 시장 규모 및 전망 차트 2022-2027 전년 대비 성장률 27% (%) 표 81: 아시아 시장 차트 – 2022-2027년 전년 대비 성장률(%) 첨부자료 139: 길리어드 사이언스(Gilead Sciences Inc.) – 주요 뉴스 o 1.1 Market overview o Exhibit 01: Executive Summary - Chart on Market Overview o Exhibit 02: Executive Summary - Data Table on Market Overview o Exhibit 03: Executive Summary - Chart on Global Market Characteristics o Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape o Exhibit 05: Executive Summary - Chart on Market Segmentation by Distribution Channel o Exhibit 06: Executive Summary - Chart on Market Segmentation by Therapy o Exhibit 07: Executive Summary - Chart on Incremental Growth o Exhibit 08: Executive Summary - Data Table on Incremental Growth o Exhibit 09: Executive Summary - Chart on Vendor Market Positioning 2 Market Landscape o 2.1 Market ecosystem o Exhibit 10: Parent market o Exhibit 11: Market Characteristics 3 Market Sizing o 3.1 Market definition o Exhibit 12: Offerings of vendors included in the market definition o 3.2 Market segment analysis o Exhibit 13: Market segments o 3.3 Market size 2022 o 3.4 Market outlook: Forecast for 2022-2027 o Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million) o Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million) o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%) o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%) 4 Historic Market Size o 4.1 Global HIV drugs market 2017 - 2021 o Exhibit 18: Historic Market Size - Data Table on global hiv drugs market 2017 - 2021 ($ million) o 4.2 Distribution Channel Segment Analysis 2017 - 2021 o Exhibit 19: Historic Market Size - Distribution Channel Segment 2017 - 2021 ($ million) o 4.3 Therapy Segment Analysis 2017 - 2021 o Exhibit 20: Historic Market Size - Therapy Segment 2017 - 2021 ($ million) o 4.4 Geography Segment Analysis 2017 - 2021 o Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million) o 4.5 Country Segment Analysis 2017 - 2021 o Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million) 5 Five Forces Analysis o 5.1 Five forces summary o Exhibit 23: Five forces analysis - Comparison between 2022 and 2027 o 5.2 Bargaining power of buyers o Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027 o 5.3 Bargaining power of suppliers o Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027 o 5.4 Threat of new entrants o Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027 o 5.5 Threat of substitutes o Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027 o 5.6 Threat of rivalry o Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027 o 5.7 Market condition o Exhibit 29: Chart on Market condition - Five forces 2022 and 2027 6 Market Segmentation by Distribution Channel o 6.1 Market segments o Exhibit 30: Chart on Distribution Channel - Market share 2022-2027 (%) o Exhibit 31: Data Table on Distribution Channel - Market share 2022-2027 (%) o 6.2 Comparison by Distribution Channel o Exhibit 32: Chart on Comparison by Distribution Channel o Exhibit 33: Data Table on Comparison by Distribution Channel o 6.3 Offline - Market size and forecast 2022-2027 o Exhibit 34: Chart on Offline - Market size and forecast 2022-2027 ($ million) o Exhibit 35: Data Table on Offline - Market size and forecast 2022-2027 ($ million) o Exhibit 36: Chart on Offline - Year-over-year growth 2022-2027 (%) o Exhibit 37: Data Table on Offline - Year-over-year growth 2022-2027 (%) o 6.4 Online - Market size and forecast 2022-2027 o Exhibit 38: Chart on Online - Market size and forecast 2022-2027 ($ million) o Exhibit 39: Data Table on Online - Market size and forecast 2022-2027 ($ million) o Exhibit 40: Chart on Online - Year-over-year growth 2022-2027 (%) o Exhibit 41: Data Table on Online - Year-over-year growth 2022-2027 (%) o 6.5 Market opportunity by Distribution Channel o Exhibit 42: Market opportunity by Distribution Channel ($ million) o Exhibit 43: Data Table on Market opportunity by Distribution Channel ($ million) 7 Market Segmentation by Therapy o 7.1 Market segments o Exhibit 44: Chart on Therapy - Market share 2022-2027 (%) o Exhibit 45: Data Table on Therapy - Market share 2022-2027 (%) o 7.2 Comparison by Therapy o Exhibit 46: Chart on Comparison by Therapy o Exhibit 47: Data Table on Comparison by Therapy o 7.3 Combination HIV medicines - Market size and forecast 2022-2027 o Exhibit 48: Chart on Combination HIV medicines - Market size and forecast 2022-2027 ($ million) o Exhibit 49: Data Table on Combination HIV medicines - Market size and forecast 2022-2027 ($ million) o Exhibit 50: Chart on Combination HIV medicines - Year-over-year growth 2022-2027 (%) o Exhibit 51: Data Table on Combination HIV medicines - Year-over-year growth 2022-2027 (%) o 7.4 Integrase inhibitors - Market size and forecast 2022-2027 o Exhibit 52: Chart on Integrase inhibitors - Market size and forecast 2022-2027 ($ million) o Exhibit 53: Data Table on Integrase inhibitors - Market size and forecast 2022-2027 ($ million) o Exhibit 54: Chart on Integrase inhibitors - Year-over-year growth 2022-2027 (%) o Exhibit 55: Data Table on Integrase inhibitors - Year-over-year growth 2022-2027 (%) o 7.5 Non-nucleoside reverse transcriptase inhibitors - Market size and forecast 2022-2027 o Exhibit 56: Chart on Non-nucleoside reverse transcriptase inhibitors - Market size and forecast 2022-2027 ($ million) o Exhibit 57: Data Table on Non-nucleoside reverse transcriptase inhibitors - Market size and forecast 2022-2027 ($ million) o Exhibit 58: Chart on Non-nucleoside reverse transcriptase inhibitors - Year-over-year growth 2022-2027 (%) o Exhibit 59: Data Table on Non-nucleoside reverse transcriptase inhibitors - Year-over-year growth 2022-2027 (%) o 7.6 Others - Market size and forecast 2022-2027 o Exhibit 60: Chart on Others - Market size and forecast 2022-2027 ($ million) o Exhibit 61: Data Table on Others - Market size and forecast 2022-2027 ($ million) o Exhibit 62: Chart on Others - Year-over-year growth 2022-2027 (%) o Exhibit 63: Data Table on Others - Year-over-year growth 2022-2027 (%) o 7.7 Market opportunity by Therapy o Exhibit 64: Market opportunity by Therapy ($ million) o Exhibit 65: Data Table on Market opportunity by Therapy ($ million) 8 Customer Landscape o 8.1 Customer landscape overview o Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 9 Geographic Landscape o 9.1 Geographic segmentation o Exhibit 67: Chart on Market share By Geographical Landscape 2022-2027 (%) o Exhibit 68: Data Table on Market share By Geographical Landscape 2022-2027 (%) o 9.2 Geographic comparison o Exhibit 69: Chart on Geographic comparison o Exhibit 70: Data Table on Geographic comparison o 9.3 North America - Market size and forecast 2022-2027 o Exhibit 71: Chart on North America - Market size and forecast 2022-2027 ($ million) o Exhibit 72: Data Table on North America - Market size and forecast 2022-2027 ($ million) o Exhibit 73: Chart on North America - Year-over-year growth 2022-2027 (%) o Exhibit 74: Data Table on North America - Year-over-year growth 2022-2027 (%) o 9.4 Europe - Market size and forecast 2022-2027 o Exhibit 75: Chart on Europe - Market size and forecast 2022-2027 ($ million) o Exhibit 76: Data Table on Europe - Market size and forecast 2022-2027 ($ million) o Exhibit 77: Chart on Europe - Year-over-year growth 2022-2027 (%) o Exhibit 78: Data Table on Europe - Year-over-year growth 2022-2027 (%) o 9.5 Asia - Market size and forecast 2022-2027 o Exhibit 79: Chart on Asia - Market size and forecast 2022-2027 ($ million) o Exhibit 80: Data Table on Asia - Market size and forecast 2022-2027 ($ million) o Exhibit 81: Chart on Asia - Year-over-year growth 2022-2027 (%) o Exhibit 82: Data Table on Asia - Year-over-year growth 2022-2027 (%) o 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 o Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) o Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) o Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) o Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) o 9.7 US - Market size and forecast 2022-2027 o Exhibit 87: Chart on US - Market size and forecast 2022-2027 ($ million) o Exhibit 88: Data Table on US - Market size and forecast 2022-2027 ($ million) o Exhibit 89: Chart on US - Year-over-year growth 2022-2027 (%) o Exhibit 90: Data Table on US - Year-over-year growth 2022-2027 (%) o 9.8 Germany - Market size and forecast 2022-2027 o Exhibit 91: Chart on Germany - Market size and forecast 2022-2027 ($ million) o Exhibit 92: Data Table on Germany - Market size and forecast 2022-2027 ($ million) o Exhibit 93: Chart on Germany - Year-over-year growth 2022-2027 (%) o Exhibit 94: Data Table on Germany - Year-over-year growth 2022-2027 (%) o 9.9 China - Market size and forecast 2022-2027 o Exhibit 95: Chart on China - Market size and forecast 2022-2027 ($ million) o Exhibit 96: Data Table on China - Market size and forecast 2022-2027 ($ million) o Exhibit 97: Chart on China - Year-over-year growth 2022-2027 (%) o Exhibit 98: Data Table on China - Year-over-year growth 2022-2027 (%) o 9.10 UK - Market size and forecast 2022-2027 o Exhibit 99: Chart on UK - Market size and forecast 2022-2027 ($ million) o Exhibit 100: Data Table on UK - Market size and forecast 2022-2027 ($ million) o Exhibit 101: Chart on UK - Year-over-year growth 2022-2027 (%) o Exhibit 102: Data Table on UK - Year-over-year growth 2022-2027 (%) o 9.11 Canada - Market size and forecast 2022-2027 o Exhibit 103: Chart on Canada - Market size and forecast 2022-2027 ($ million) o Exhibit 104: Data Table on Canada - Market size and forecast 2022-2027 ($ million) o Exhibit 105: Chart on Canada - Year-over-year growth 2022-2027 (%) o Exhibit 106: Data Table on Canada - Year-over-year growth 2022-2027 (%) o 9.12 Market opportunity By Geographical Landscape o Exhibit 107: Market opportunity By Geographical Landscape ($ million) o Exhibit 108: Data Tables on Market opportunity By Geographical Landscape ($ million) 10 Drivers, Challenges, and Trends o 10.1 Market drivers o 10.2 Market challenges o 10.3 Impact of drivers and challenges o Exhibit 109: Impact of drivers and challenges in 2022 and 2027 o 10.4 Market trends 11 Vendor Landscape o 11.1 Overview o 11.2 Vendor landscape o Exhibit 110: Overview on Criticality of inputs and Factors of differentiation o 11.3 Landscape disruption o Exhibit 111: Overview on factors of disruption o 11.4 Industry risks o Exhibit 112: Impact of key risks on business 12 Vendor Analysis o 12.1 Vendors covered o Exhibit 113: Vendors covered o 12.2 Market positioning of vendors o Exhibit 114: Matrix on vendor position and classification o 12.3 AbbVie Inc. o Exhibit 115: AbbVie Inc. - Overview o Exhibit 116: AbbVie Inc. - Product / Service o Exhibit 117: AbbVie Inc. - Key news o Exhibit 118: AbbVie Inc. - Key offerings o 12.4 Aurobindo Pharma Ltd. o Exhibit 119: Aurobindo Pharma Ltd. - Overview o Exhibit 120: Aurobindo Pharma Ltd. - Product / Service o Exhibit 121: Aurobindo Pharma Ltd. - Key offerings o 12.5 Bristol Myers Squibb Co. o Exhibit 122: Bristol Myers Squibb Co. - Overview o Exhibit 123: Bristol Myers Squibb Co. - Product / Service o Exhibit 124: Bristol Myers Squibb Co. - Key news o Exhibit 125: Bristol Myers Squibb Co. - Key offerings o 12.6 Cadila Pharmaceuticals Ltd. o Exhibit 126: Cadila Pharmaceuticals Ltd. - Overview o Exhibit 127: Cadila Pharmaceuticals Ltd. - Product / Service o Exhibit 128: Cadila Pharmaceuticals Ltd. - Key offerings o 12.7 Cipla Ltd. o Exhibit 129: Cipla Ltd. - Overview o Exhibit 130: Cipla Ltd. - Business segments o Exhibit 131: Cipla Ltd. - Key news o Exhibit 132: Cipla Ltd. - Key offerings o Exhibit 133: Cipla Ltd. - Segment focus o 12.8 Emcure Pharmaceuticals Ltd. o Exhibit 134: Emcure Pharmaceuticals Ltd. - Overview o Exhibit 135: Emcure Pharmaceuticals Ltd. - Product / Service o Exhibit 136: Emcure Pharmaceuticals Ltd. - Key offerings o 12.9 Gilead Sciences Inc. o Exhibit 137: Gilead Sciences Inc. - Overview o Exhibit 138: Gilead Sciences Inc. - Product / Service o Exhibit 139: Gilead Sciences Inc. - Key news o Exhibit 140: Gilead Sciences Inc. - Key offerings o 12.10 GlaxoSmithKline Plc o Exhibit 141: GlaxoSmithKline Plc - Overview o Exhibit 142: GlaxoSmithKline Plc - Business segments o Exhibit 143: GlaxoSmithKline Plc - Key news o Exhibit 144: GlaxoSmithKline Plc - Key offerings o Exhibit 145: GlaxoSmithKline Plc - Segment focus o 12.11 Hetero Labs Ltd. o Exhibit 146: Hetero Labs Ltd. - Overview o Exhibit 147: Hetero Labs Ltd. - Product / Service o Exhibit 148: Hetero Labs Ltd. - Key offerings o 12.12 Johnson and Johnson Services Inc. o Exhibit 149: Johnson and Johnson Services Inc. - Overview o Exhibit 150: Johnson and Johnson Services Inc. - Business segments o Exhibit 151: Johnson and Johnson Services Inc. - Key news o Exhibit 152: Johnson and Johnson Services Inc. - Key offerings o Exhibit 153: Johnson and Johnson Services Inc. - Segment focus o 12.13 Lupin Ltd. o Exhibit 154: Lupin Ltd. - Overview o Exhibit 155: Lupin Ltd. - Product / Service o Exhibit 156: Lupin Ltd. - Key news o Exhibit 157: Lupin Ltd. - Key offerings o 12.14 Merck and Co. Inc. o Exhibit 158: Merck and Co. Inc. - Overview o Exhibit 159: Merck and Co. Inc. - Business segments o Exhibit 160: Merck and Co. Inc. - Key news o Exhibit 161: Merck and Co. Inc. - Key offerings o Exhibit 162: Merck and Co. Inc. - Segment focus o 12.15 Sun Pharmaceutical Industries Ltd. o Exhibit 163: Sun Pharmaceutical Industries Ltd. - Overview o Exhibit 164: Sun Pharmaceutical Industries Ltd. - Product / Service o Exhibit 165: Sun Pharmaceutical Industries Ltd. - Key offerings o 12.16 Teva Pharmaceutical Industries Ltd. o Exhibit 166: Teva Pharmaceutical Industries Ltd. - Overview o Exhibit 167: Teva Pharmaceutical Industries Ltd. - Business segments o Exhibit 168: Teva Pharmaceutical Industries Ltd. - Key news o Exhibit 169: Teva Pharmaceutical Industries Ltd. - Key offerings o Exhibit 170: Teva Pharmaceutical Industries Ltd. - Segment focus o 12.17 Viatris Inc. o Exhibit 171: Viatris Inc. - Overview o Exhibit 172: Viatris Inc. - Business segments o Exhibit 173: Viatris Inc. - Key news o Exhibit 174: Viatris Inc. - Key offerings o Exhibit 175: Viatris Inc. - Segment focus 13 Appendix o 13.1 Scope of the report o 13.2 Inclusions and exclusions checklist o Exhibit 176: Inclusions checklist o Exhibit 177: Exclusions checklist o 13.3 Currency conversion rates for US$ o Exhibit 178: Currency conversion rates for US$ o 13.4 Research methodology o Exhibit 179: Research methodology o Exhibit 180: Validation techniques employed for market sizing o Exhibit 181: Information sources o 13.5 List of abbreviations o Exhibit 182: List of abbreviations Exhibits: Exhibits1: Executive Summary - Chart on Market Overview Exhibits2: Executive Summary - Data Table on Market Overview Exhibits3: Executive Summary - Chart on Global Market Characteristics Exhibits4: Executive Summary - Chart on Market By Geographical Landscape Exhibits5: Executive Summary - Chart on Market Segmentation by Distribution Channel Exhibits6: Executive Summary - Chart on Market Segmentation by Therapy Exhibits7: Executive Summary - Chart on Incremental Growth Exhibits8: Executive Summary - Data Table on Incremental Growth Exhibits9: Executive Summary - Chart on Vendor Market Positioning Exhibits10: Parent market Exhibits11: Market Characteristics Exhibits12: Offerings of vendors included in the market definition Exhibits13: Market segments Exhibits14: Chart on Global - Market size and forecast 2022-2027 ($ million) Exhibits15: Data Table on Global - Market size and forecast 2022-2027 ($ million) Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%) Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%) Exhibits18: Historic Market Size - Data Table on global hiv drugs market 2017 - 2021 ($ million) Exhibits19: Historic Market Size - Distribution Channel Segment 2017 - 2021 ($ million) Exhibits20: Historic Market Size - Therapy Segment 2017 - 2021 ($ million) Exhibits21: Historic Market Size - Geography Segment 2017 - 2021 ($ million) Exhibits22: Historic Market Size - Country Segment 2017 - 2021 ($ million) Exhibits23: Five forces analysis - Comparison between 2022 and 2027 Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027 Exhibits25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027 Exhibits26: Threat of new entrants - Impact of key factors in 2022 and 2027 Exhibits27: Threat of substitutes - Impact of key factors in 2022 and 2027 Exhibits28: Threat of rivalry - Impact of key factors in 2022 and 2027 Exhibits29: Chart on Market condition - Five forces 2022 and 2027 Exhibits30: Chart on Distribution Channel - Market share 2022-2027 (%) Exhibits31: Data Table on Distribution Channel - Market share 2022-2027 (%) Exhibits32: Chart on Comparison by Distribution Channel Exhibits33: Data Table on Comparison by Distribution Channel Exhibits34: Chart on Offline - Market size and forecast 2022-2027 ($ million) Exhibits35: Data Table on Offline - Market size and forecast 2022-2027 ($ million) Exhibits36: Chart on Offline - Year-over-year growth 2022-2027 (%) Exhibits37: Data Table on Offline - Year-over-year growth 2022-2027 (%) Exhibits38: Chart on Online - Market size and forecast 2022-2027 ($ million) Exhibits39: Data Table on Online - Market size and forecast 2022-2027 ($ million) Exhibits40: Chart on Online - Year-over-year growth 2022-2027 (%) Exhibits41: Data Table on Online - Year-over-year growth 2022-2027 (%) Exhibits42: Market opportunity by Distribution Channel ($ million) Exhibits43: Data Table on Market opportunity by Distribution Channel ($ million) Exhibits44: Chart on Therapy - Market share 2022-2027 (%) Exhibits45: Data Table on Therapy - Market share 2022-2027 (%) Exhibits46: Chart on Comparison by Therapy Exhibits47: Data Table on Comparison by Therapy Exhibits48: Chart on Combination HIV medicines - Market size and forecast 2022-2027 ($ million) Exhibits49: Data Table on Combination HIV medicines - Market size and forecast 2022-2027 ($ million) Exhibits50: Chart on Combination HIV medicines - Year-over-year growth 2022-2027 (%) Exhibits51: Data Table on Combination HIV medicines - Year-over-year growth 2022-2027 (%) Exhibits52: Chart on Integrase inhibitors - Market size and forecast 2022-2027 ($ million) Exhibits53: Data Table on Integrase inhibitors - Market size and forecast 2022-2027 ($ million) Exhibits54: Chart on Integrase inhibitors - Year-over-year growth 2022-2027 (%) Exhibits55: Data Table on Integrase inhibitors - Year-over-year growth 2022-2027 (%) Exhibits56: Chart on Non-nucleoside reverse transcriptase inhibitors - Market size and forecast 2022-2027 ($ million) Exhibits57: Data Table on Non-nucleoside reverse transcriptase inhibitors - Market size and forecast 2022-2027 ($ million) Exhibits58: Chart on Non-nucleoside reverse transcriptase inhibitors - Year-over-year growth 2022-2027 (%) Exhibits59: Data Table on Non-nucleoside reverse transcriptase inhibitors - Year-over-year growth 2022-2027 (%) Exhibits60: Chart on Others - Market size and forecast 2022-2027 ($ million) Exhibits61: Data Table on Others - Market size and forecast 2022-2027 ($ million) Exhibits62: Chart on Others - Year-over-year growth 2022-2027 (%) Exhibits63: Data Table on Others - Year-over-year growth 2022-2027 (%) Exhibits64: Market opportunity by Therapy ($ million) Exhibits65: Data Table on Market opportunity by Therapy ($ million) Exhibits66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria Exhibits67: Chart on Market share By Geographical Landscape 2022-2027 (%) Exhibits68: Data Table on Market share By Geographical Landscape 2022-2027 (%) Exhibits69: Chart on Geographic comparison Exhibits70: Data Table on Geographic comparison Exhibits71: Chart on North America - Market size and forecast 2022-2027 ($ million) Exhibits72: Data Table on North America - Market size and forecast 2022-2027 ($ million) Exhibits73: Chart on North America - Year-over-year growth 2022-2027 (%) Exhibits74: Data Table on North America - Year-over-year growth 2022-2027 (%) Exhibits75: Chart on Europe - Market size and forecast 2022-2027 ($ million) Exhibits76: Data Table on Europe - Market size and forecast 2022-2027 ($ million) Exhibits77: Chart on Europe - Year-over-year growth 2022-2027 (%) Exhibits78: Data Table on Europe - Year-over-year growth 2022-2027 (%) Exhibits79: Chart on Asia - Market size and forecast 2022-2027 ($ million) Exhibits80: Data Table on Asia - Market size and forecast 2022-2027 ($ million) Exhibits81: Chart on Asia - Year-over-year growth 2022-2027 (%) Exhibits82: Data Table on Asia - Year-over-year growth 2022-2027 (%) Exhibits83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibits84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibits85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) Exhibits86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) Exhibits87: Chart on US - Market size and forecast 2022-2027 ($ million) Exhibits88: Data Table on US - Market size and forecast 2022-2027 ($ million) Exhibits89: Chart on US - Year-over-year growth 2022-2027 (%) Exhibits90: Data Table on US - Year-over-year growth 2022-2027 (%) Exhibits91: Chart on Germany - Market size and forecast 2022-2027 ($ million) Exhibits92: Data Table on Germany - Market size and forecast 2022-2027 ($ million) Exhibits93: Chart on Germany - Year-over-year growth 2022-2027 (%) Exhibits94: Data Table on Germany - Year-over-year growth 2022-2027 (%) Exhibits95: Chart on China - Market size and forecast 2022-2027 ($ million) Exhibits96: Data Table on China - Market size and forecast 2022-2027 ($ million) Exhibits97: Chart on China - Year-over-year growth 2022-2027 (%) Exhibits98: Data Table on China - Year-over-year growth 2022-2027 (%) Exhibits99: Chart on UK - Market size and forecast 2022-2027 ($ million) Exhibits100: Data Table on UK - Market size and forecast 2022-2027 ($ million) Exhibits101: Chart on UK - Year-over-year growth 2022-2027 (%) Exhibits102: Data Table on UK - Year-over-year growth 2022-2027 (%) Exhibits103: Chart on Canada - Market size and forecast 2022-2027 ($ million) Exhibits104: Data Table on Canada - Market size and forecast 2022-2027 ($ million) Exhibits105: Chart on Canada - Year-over-year growth 2022-2027 (%) Exhibits106: Data Table on Canada - Year-over-year growth 2022-2027 (%) Exhibits107: Market opportunity By Geographical Landscape ($ million) Exhibits108: Data Tables on Market opportunity By Geographical Landscape ($ million) Exhibits109: Impact of drivers and challenges in 2022 and 2027 Exhibits110: Overview on Criticality of inputs and Factors of differentiation Exhibits111: Overview on factors of disruption Exhibits112: Impact of key risks on business Exhibits113: Vendors covered Exhibits114: Matrix on vendor position and classification Exhibits115: AbbVie Inc. - Overview Exhibits116: AbbVie Inc. - Product / Service Exhibits117: AbbVie Inc. - Key news Exhibits118: AbbVie Inc. - Key offerings Exhibits119: Aurobindo Pharma Ltd. - Overview Exhibits120: Aurobindo Pharma Ltd. - Product / Service Exhibits121: Aurobindo Pharma Ltd. - Key offerings Exhibits122: Bristol Myers Squibb Co. - Overview Exhibits123: Bristol Myers Squibb Co. - Product / Service Exhibits124: Bristol Myers Squibb Co. - Key news Exhibits125: Bristol Myers Squibb Co. - Key offerings Exhibits126: Cadila Pharmaceuticals Ltd. - Overview Exhibits127: Cadila Pharmaceuticals Ltd. - Product / Service Exhibits128: Cadila Pharmaceuticals Ltd. - Key offerings Exhibits129: Cipla Ltd. - Overview Exhibits130: Cipla Ltd. - Business segments Exhibits131: Cipla Ltd. - Key news Exhibits132: Cipla Ltd. - Key offerings Exhibits133: Cipla Ltd. - Segment focus Exhibits134: Emcure Pharmaceuticals Ltd. - Overview Exhibits135: Emcure Pharmaceuticals Ltd. - Product / Service Exhibits136: Emcure Pharmaceuticals Ltd. - Key offerings Exhibits137: Gilead Sciences Inc. - Overview Exhibits138: Gilead Sciences Inc. - Product / Service Exhibits139: Gilead Sciences Inc. - Key news Exhibits140: Gilead Sciences Inc. - Key offerings Exhibits141: GlaxoSmithKline Plc - Overview Exhibits142: GlaxoSmithKline Plc - Business segments Exhibits143: GlaxoSmithKline Plc - Key news Exhibits144: GlaxoSmithKline Plc - Key offerings Exhibits145: GlaxoSmithKline Plc - Segment focus Exhibits146: Hetero Labs Ltd. - Overview Exhibits147: Hetero Labs Ltd. - Product / Service Exhibits148: Hetero Labs Ltd. - Key offerings Exhibits149: Johnson and Johnson Services Inc. - Overview Exhibits150: Johnson and Johnson Services Inc. - Business segments Exhibits151: Johnson and Johnson Services Inc. - Key news Exhibits152: Johnson and Johnson Services Inc. - Key offerings Exhibits153: Johnson and Johnson Services Inc. - Segment focus Exhibits154: Lupin Ltd. - Overview Exhibits155: Lupin Ltd. - Product / Service Exhibits156: Lupin Ltd. - Key news Exhibits157: Lupin Ltd. - Key offerings Exhibits158: Merck and Co. Inc. - Overview Exhibits159: Merck and Co. Inc. - Business segments Exhibits160: Merck and Co. Inc. - Key news Exhibits161: Merck and Co. Inc. - Key offerings Exhibits162: Merck and Co. Inc. - Segment focus Exhibits163: Sun Pharmaceutical Industries Ltd. - Overview Exhibits164: Sun Pharmaceutical Industries Ltd. - Product / Service Exhibits165: Sun Pharmaceutical Industries Ltd. - Key offerings Exhibits166: Teva Pharmaceutical Industries Ltd. - Overview Exhibits167: Teva Pharmaceutical Industries Ltd. - Business segments Exhibits168: Teva Pharmaceutical Industries Ltd. - Key news Exhibits169: Teva Pharmaceutical Industries Ltd. - Key offerings Exhibits170: Teva Pharmaceutical Industries Ltd. - Segment focus Exhibits171: Viatris Inc. - Overview Exhibits172: Viatris Inc. - Business segments Exhibits173: Viatris Inc. - Key news Exhibits174: Viatris Inc. - Key offerings Exhibits175: Viatris Inc. - Segment focus Exhibits176: Inclusions checklist Exhibits177: Exclusions checklist Exhibits178: Currency conversion rates for US$ Exhibits179: Research methodology Exhibits180: Validation techniques employed for market sizing Exhibits181: Information sources Exhibits182: List of abbreviations |
| ※참고 정보 HIV 치료제는 인간 면역 결핍 바이러스(HIV) 감염을 관리하고 치료하기 위해 개발된 약물입니다. HIV는 인체 면역계의 주요 세포인 CD4 T 세포를 감염시켜 면역력을 약화시키고, 결국에는 에이즈(AIDS)로 발전할 수 있는 질병을 유발합니다. HIV 감염은 전세계적으로 심각한 공공 보건 문제로, 치료 없이는 감염자가 생존하는 데 큰 어려움을 겪게 됩니다. 이러한 이유로 HIV 치료제는 감염자의 생존율과 삶의 질을 향상시키는 중요한 역할을 합니다. HIV 치료제의 주요 개념은 바이러스를 완전히 제거하는 것이 아니라, 바이러스의 복제를 억제하여 면역계가 안전하게 기능할 수 있도록 돕는 것입니다. 이를 통해 HIV 감염자는 장기간 동안 건강 상태를 유지하고, 동정하에 전염 가능성을 크게 줄일 수 있습니다. 이러한 치료는 일반적으로 항레트로바이러스 치료(ART)라고 불리며, 여러 종류의 약물이 조합되어 사용됩니다. HIV 치료제는 크게 세 가지 주요 범주로 나눌 수 있습니다. 첫 번째는 역전사효소 억제제(NRTI, NNRTI)로, 이들은 HIV가 자신의 RNA를 DNA로 변환하는 과정에서 핵심적인 역할을 하는 효소인 역전사효소를 차단하여 바이러스의 복제를 저지합니다. 두 번째는 프로테아제 억제제(PI)로, HIV가 새로운 바이러스 입자를 생성하는 데 필요한 프로테아제 효소의 작용을 방해하여 바이러스의 증식을 억제합니다. 마지막으로 인테그레이즈 억제제(INI)는 HIV의 DNA가 숙주 세포의 유전자에 통합되는 과정을 차단하여 바이러스의 생명을 저해합니다. HIV 치료제의 용도는 여러 가지가 있으며, 가장 기본적으로는 HIV 감염자에게 지속적인 생명 연장을 제공하는 것입니다. 추가적으로, 치료를 통해 HIV 환자는 수년간 건강한 생활을 영위할 수 있으며, 비감염 상태를 유지하여 성적 파트너에게 전염될 위험성을 크게 줄일 수 있습니다. 또한, 임신 중 감염된 여성의 경우 ART를 통해 태아에게 전염되는 것을 예방할 수 있습니다. 이와 같은 다양한 용도 덕분에 HIV 치료제는 감염자의 삶에 긍정적인 영향을 미치고 있습니다. HIV 치료와 관련된 기술도 중요한 발전을 이루고 있습니다. 예를 들어, 약물의 효능을 높이고 부작용을 줄이기 위한 분야별 연구가 활발히 진행되고 있습니다. 약물의 전용 방법이나 조합 요법은 개별 patient's에 맞게 조정되어 더 나은 치료 결과를 가져올 수 있습니다. 최근에는 장기형 주사제나 경구용 약물들이 개발되어 복용 편의성이 대폭 향상된 경우도 있습니다. 더 나아가, 유전자 편집 기술이나 백신 개발이 HIV 예방과 치료에 기여할 수 있는 가능성을 보여주고 있습니다. 결론적으로, HIV 치료제는 생명과 건강의 중요한 요소로 작용하며, 감염자의 삶의 질을 향상시키는 데 필수적인 역할을 합니다. 다양한 종류의 약물이 존재하고, 기술의 발전을 통해 더 효과적인 치료 방법이 개발되고 있습니다. 이러한 노력은 HIV 감염자들이 건강한 삶을 영위할 수 있게 하고, 사회 전체적으로 감염의 확산을 줄이는 데 큰 기여를 하고 있습니다. |
| ※본 조사보고서 [글로벌 HIV 치료제 시장 2023-2027 : 오프라인, 온라인] (코드 : IRTNTR75747-23) 판매에 관한 면책사항을 반드시 확인하세요. |
| ※본 조사보고서 [글로벌 HIV 치료제 시장 2023-2027 : 오프라인, 온라인] 에 대해서 E메일 문의는 여기를 클릭하세요. |

